VIDEO: Evolution of AMD medication delivery

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The biggest change in treating patients with interventional injections in the past few years really has been around the use of prophylactic antibiotics. The recommendations have otherwise remained unchanged. With regards to using lid speculum, betadine for sterilization, the ocular surface. There has been some movement around using other potential drugs for sterilizations but those haven't really taken effect. And there has been some controversy around the use of viscous lidocaine as a as a medication to anesthetize patients because there is a perceived risk of higher end ophthalmologists in those populations. In the future, I perceive that again, a lot of this stuff will move into a sustained delivery model of some sort. Maybe it will be for example, the Port Delivery System. Which has readouts now of the phase three. It will also be a different mechanism action we may inhibit. For example the first Map studies, have shown really a significant durability with both a combined inch two and combine anti-VEGF effect in those patient populations. And potentially gene therapy, depending on how it's delivered either intravitreal or subretinally. Those are really two attractive ways of reducing the overall treatment burden. And I think the vast majority of patients should feel really sure that we just have so many potential ways of improving their sight. But also reducing their burden of treatment over time.